17 research outputs found

    Abnormal Brain Iron Metabolism in Irp2 Deficient Mice Is Associated with Mild Neurological and Behavioral Impairments

    Get PDF
    Iron Regulatory Protein 2 (Irp2, Ireb2) is a central regulator of cellular iron homeostasis in vertebrates. Two global knockout mouse models have been generated to explore the role of Irp2 in regulating iron metabolism. While both mouse models show that loss of Irp2 results in microcytic anemia and altered body iron distribution, discrepant results have drawn into question the role of Irp2 in regulating brain iron metabolism. One model shows that aged Irp2 deficient mice develop adult-onset progressive neurodegeneration that is associated with axonal degeneration and loss of Purkinje cells in the central nervous system. These mice show iron deposition in white matter tracts and oligodendrocyte soma throughout the brain. A contrasting model of global Irp2 deficiency shows no overt or pathological signs of neurodegeneration or brain iron accumulation, and display only mild motor coordination and balance deficits when challenged by specific tests. Explanations for conflicting findings in the severity of the clinical phenotype, brain iron accumulation and neuronal degeneration remain unclear. Here, we describe an additional mouse model of global Irp2 deficiency. Our aged Irp2−/− mice show marked iron deposition in white matter and in oligodendrocytes while iron content is significantly reduced in neurons. Ferritin and transferrin receptor 1 (TfR1, Tfrc), expression are increased and decreased, respectively, in the brain from Irp2−/− mice. These mice show impairments in locomotion, exploration, motor coordination/balance and nociception when assessed by neurological and behavioral tests, but lack overt signs of neurodegenerative disease. Ultrastructural studies of specific brain regions show no evidence of neurodegeneration. Our data suggest that Irp2 deficiency dysregulates brain iron metabolism causing cellular dysfunction that ultimately leads to mild neurological, behavioral and nociceptive impairments

    Smad1/5 is required for erythropoietin-mediated suppression of hepcidin in mice

    No full text
    Anemia suppresses liver hepcidin expression to supply adequate iron for erythropoiesis. Erythroferrone mediates hepcidin suppression by anemia, but its mechanism of action remains uncertain. The bone morphogenetic protein (BMP)-SMAD signaling pathway has a central role in hepcidin transcriptional regulation. Here, we explored the contribution of individual receptor-activated SMADs in hepcidin regulation and their involvement in erythroferrone suppression of hepcidin. In Hep3B cells, SMAD5 or SMAD1 but not SMAD8, knockdown inhibited hepcidin (HAMP) messenger RNA (mRNA) expression. Hepatocyte-specific double-knockout Smad1 fl/fl ;Smad5 fl/fl ;Cre + mice exhibited ∼90% transferrin saturation and massive liver iron overload, whereas Smad1 fl/fl ;Smad5 fl/wt ;Cre + mice or Smad1 fl/wt ;Smad5 fl/fl ;Cre + female mice with 1 functional Smad5 or Smad1 allele had modestly increased serum and liver iron, and single-knockout Smad5 fl/fl ;Cre + or Smad1 fl/fl ;Cre + mice had minimal to no iron loading, suggesting a gene dosage effect. Hamp mRNA was reduced in all Cre+ mouse livers at 12 days and in all Cre+ primary hepatocytes. However, only double-knockout mice continued to exhibit low liver Hamp at 8 weeks and failed to induce Hamp in response to Bmp6 in primary hepatocyte cultures. Epoetin alfa (EPO) robustly induced bone marrow erythroferrone (Fam132b) mRNA in control and Smad1 fl/fl ;Smad5 fl/fl ;Cre + mice but suppressed hepcidin only in control mice. Likewise, erythroferrone failed to decrease Hamp mRNA in Smad1 fl/fl ;Smad5 fl/fl ;Cre + primary hepatocytes and SMAD1/SMAD5 knockdown Hep3B cells. EPO and erythroferrone reduced liver Smad1/5 phosphorylation in parallel with Hamp mRNA in control mice and Hep3B cells. Thus, Smad1 and Smad5 have overlapping functions to govern hepcidin transcription. Moreover, erythropoietin and erythroferrone target Smad1/5 signaling and require Smad1/5 to suppress hepcidin expression.status: publishe

    Activin B induces noncanonical SMAD1/5/8 signaling via BMP type I receptors in hepatocytes: Evidence for a role in hepcidin induction by inflammation in male mice

    No full text
    Induction of the iron regulatory hormone hepcidin contributes to the anemia of inflammation. Bone morphogenetic protein 6 (BMP6) signaling is a central regulator of hepcidin expression in the liver. Recently, the TGF-β/BMPsuperfamily member activin B was implicated in hepcidin induction by inflammation via noncanonical SMAD1/5/8 signaling, but its mechanism of action and functional significance in vivo remain uncertain. Here, we show that low concentrations of activin B, but not activin A, stimulate prolonged SMAD1/5/8 signaling and hepcidin expression in liver cells to a similar degree as canonical SMAD2β signaling, and with similar or modestly reduced potency compared with BMP6. Activin B stimulates hepcidin via classical activin type II receptors ACVR2A and ACVR2B, noncanonical BMP type I receptors activin receptor-like kinase 2 and activin receptorlike kinase 3, and SMAD5. The coreceptor hemojuvelin binds to activin B and facilitates activin B-SMAD1/5/8 signaling. Activin B-SMAD1/5/8 signaling has some selectivity for hepatocyte-derived cells and is not enabled by hemojuvelin in other cell types. Liver activin B mRNA expression is up-regulated in multiple mouse models of inflammation associated with increased hepcidin and hypoferremia, including lipopolysaccharide, turpentine, and heat-killed Brucella abortus models. Finally, the activin inhibitor follistatin-315 blunts hepcidin induction by lipopolysaccharide or B. abortus in mice. Our data elucidate a novel mechanism for noncanonical SMAD activation and support a likely functional role for activin B in hepcidin stimulation during inflammation in vivo

    Irp2 regulates insulin production through iron-mediated Cdkal1-catalyzed tRNA modification

    Get PDF
    Regulation of cellular iron homeostasis is crucial as both iron excess and deficiency cause hematological and neurodegenerative diseases. Here we show that mice lacking iron-regulatory protein 2 (Irp2), a regulator of cellular iron homeostasis, develop diabetes. Irp2 post-transcriptionally regulates the iron-uptake protein transferrin receptor 1 (TfR1) and the iron-storage protein ferritin, and dysregulation of these proteins due to Irp2 loss causes functional iron deficiency in β cells. This impairs Fe–S cluster biosynthesis, reducing the function of Cdkal1, an Fe–S cluster enzyme that catalyzes methylthiolation of t6A37 in tRNALysUUU to ms2t6A37. As a consequence, lysine codons in proinsulin are misread and proinsulin processing is impaired, reducing insulin content and secretion. Iron normalizes ms2t6A37 and proinsulin lysine incorporation, restoring insulin content and secretion in Irp2−/− β cells. These studies reveal a previously unidentified link between insulin processing and cellular iron deficiency that may have relevance to type 2 diabetes in humans

    Tissue iron content of aged male <i>Irp2<sup>−/−</sup></i> and WT mice.

    No full text
    <p>Total iron content was determined by inductively-coupled plasma optical emission spectroscopy (ICP-OES). Statistical analysis performed by Student's paired t-test (*<i>p</i><0.05; ***<i>p</i><0.001, mean (µg Fe/mg wet tissue weight) ×100± SEM). Ages of mice: WT, 64–75 weeks; <i>Irp2<sup>−/−</sup></i>, 49–71 weeks.</p

    Locomotion, motor coordination and nociception are impaired in <i>Irp2<sup>−/−</sup></i> mice.

    No full text
    <p><i>Irp2<sup>−/−</sup></i> mice display reduced horizontal locomotor activity (total distance traveled, number of turns, number of total line crossings, mean velocity and angular velocity), and <i>B</i>) reduced vertical exploratory activity (number of rearing and rearing latency) assessed by the modified-Hole Board test <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0098072#pone.0098072-Ohl1" target="_blank">[31]</a>. <i>C) Left panel,</i> performance of <i>Irp2<sup>−/−</sup></i> and WT mice on the accelerating rotarod in four trials on four consecutive trials with 15 min inter-trial-interval; <i>right panel</i>, decreased mean latency of <i>Irp2<sup>−/−</sup></i> mice to fall off the rotarod (n = 4 trial; <i>p</i> = 0.055). <i>D)</i> 4-paw grip force test shows no difference in muscular strength between <i>Irp2<sup>−/−</sup></i> and WT mice. <i>E)</i> Hot plate test shows increased hind paw licking in <i>Irp2<sup>−/−</sup></i> mice. Data are given as the mean ± SEM; *<i>p</i><0.05; <sup>**</sup><i>p</i><0.01, ***<i>p</i><0.001, relative to WT; WT (n = 9) and <i>Irp2<sup>−/−</sup></i> (n = 10).</p
    corecore